和黄医药2025年收入5.5亿美元，现金14亿美元：ATTC平台进入临床验证

Core Viewpoint - The company is focusing on the development of its ATTC (Antibody-Drug Conjugate) platform and plans to seek partnerships with multinational pharmaceutical companies for the development of ATTC candidate drugs in 2026 [9]. Financial Performance - For the fiscal year ending December 31, 2025, the company's revenue is projected to be $548.5 million, an increase from $630.2 million in 2024 [2]. - The net income attributable to the company for 2025 is expected to be $456.9 million, significantly up from $37.7 million in 2024, primarily due to a $415.8 million after-tax gain from the sale of a stake in Shanghai Hengrui Medicine [2]. - As of the end of 2025, the company’s cash reserves are expected to total $1.3673 billion, up from $836.1 million the previous year, providing ample funding for the global development of its ATTC platform [2]. Market Performance - As of March 6, the stock price of the company increased by 8.4%, with an intraday high of 9.6% [3]. - The total market sales for 2025, including products like FRUZAQLA®, Aiyoute®, Suotai Da®, and Worisha®, are projected to grow by 5% to reach $524.7 million [5]. Product Development - The overseas sales of FRUZAQLA® (Fruquintinib) increased by 26% to $36.62 million, covering 38 countries, with nearly 20 countries included in health insurance [5]. - The company has received approval for a third indication for lung cancer for Worisha® (Savolitinib), triggering a $11 million milestone payment from AstraZeneca [5]. - The clinical pipeline is advancing, with the ESLIM-02 Phase III study achieving its primary endpoint in autoimmune hemolytic anemia, and plans to submit a new drug application in the first half of 2026 [6]. ATTC Platform Development - The ATTC platform has entered clinical trial stages, with the first candidate drug HMPL-A251 starting global Phase I/IIa trials in December [8]. - The company plans to accelerate global investment in the ATTC projects, with a focus on innovative drug development in oncology [10].